Featured Poster Session III: Ovarian Cancer: Innovations and Controversies
Sunday, March 23, 2014: 12:45 PM-1:30 PM
West Exhibit Hall (Tampa Convention Center)
Description: CME will not be offered for this session.
Featured Poster Session Moderator: Anil K. Sood, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
12:45 PM
Moderator Introductions
A. K. Sood
The University of Texas MD Anderson Cancer Center, Houston, TX
12:50 PM
An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs serous carcinoma treated with platinum therapy: a Gynecologic Oncology Group (GOG) experience
K. E. Oliver1, W. E. Brady2, M. J. Birrer3, D. M. Gershenson4, G. Fleming5 and J. H. Farley6
1Walter Reed National Military Medical Center, Bethesda, MD, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Massachusetts General Hospital/Harvard University, Boston, MA, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5University of Chicago Medical Center, Chicago, IL, 6St. Joseph's Hospital and Medical Center, Phoenix, AZ
12:52 PM
Comparative effectiveness of treatments for recurrent ovarian cancer
N. A. Bickell1, P. Deb2, M. P. Hayes1, R. Franco1, J. Wisnivesky1, E. A. Howell1, R. Sun2 and N. Egorova1
1The Mount Sinai School of Medicine, New York, NY, 2CUNY Hunter College, New York, NY
12:54 PM
Discussant
A. K. Sood
The University of Texas MD Anderson Cancer Center, Houston, TX
12:59 PM
Short-term morbidity and mortality associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent/advanced-stage ovarian cancer
J. C. Cripe II1, J. Tseng2, R. N. Eskander1, S. D. Thompson2, A. Nickles Fader2, E. J. Tanner III2 and R. E. Bristow3
1University of California at Irvine Medical Center, Orange, CA, 2Johns Hopkins Medical Institutions, Baltimore, MD, 3University of California, Irvine, Irvine, CA
1:01 PM
Primary debulking surgery or neoadjuvant chemotherapy: what is the optimal treatment approach for obese patients with ovarian/fallopian tube/primary peritoneal carcinoma?
M. J. Worley Jr.1, S. Guseh1, J. A. Rauh-Hain2, K. M. Esselen1, M. G. Muto1, C. M. Feltmate3, R. S. Berkowitz1, M. G. Del Carmen2, J. O. Schorge2 and N. S. Horowitz4
1Brigham and Women's Hospital/Harvard University, Boston, MA, 2Massachusetts General Hospital/Harvard University, Boston, MA, 3Brigham and Women's Hospital and Harvard University, Boston, MA, 4Harvard University, Boston, MA
1:03 PM
Launching personalized surgical therapy for advanced ovarian cancer
A. M. Nick1, P. T. Ramirez1, K. M. Rangel1, K. M. Schmeler1, P. T. Soliman1, J. K. Burzawa1, M. Kodama2, K. H. Lu1, R. L. Coleman1 and A. K. Sood1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Osaka University Graduate School of Medicine, Suita, Japan
1:05 PM
Discussant
L. W. Rice
University of Wisconsin School of Medicine and Public Health, Madison, WI
1:10 PM
Debate: Neoadjuvant Chemotherapy (Pro)
A. Berchuck
Duke University Medical Center, Durham, NC
1:17 PM
Debate: Neoadjuvant Chemotherapy (Con)
B. Y. Karlan
Cedars-Sinai Medical Center, Los Angeles, CA
1:24 PM
Question & Floor Discussion
